Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) CFO James M. Frates sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $47.41, for a total value of $331,870.00. Following the transaction, the chief financial officer now directly owns 44,225 shares of the company’s stock, valued at approximately $2,096,707. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 1.21% on Friday, hitting $48.38. 374,217 shares of the company’s stock traded hands. Alkermes Plc has a 52 week low of $28.86 and a 52 week high of $54.25. The stock has a 50-day moving average of $48.25 and a 200-day moving average of $46.7. The company’s market cap is $6.992 billion.

Alkermes Plc (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the previous year, the company posted $0.40 earnings per share. The company’s revenue for the quarter was down 20.3% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.49 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday. They now have a $50.00 price target on the stock. Separately, analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Alkermes Plc presently has a consensus rating of “Buy” and a consensus target price of $49.50.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.